Centre Hospitalier Poissy-Saint Germain
Poissy, 78300, France
NCT Number: NCT06572761
The purpose of this study is to determine whether a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) are effective to prolong pregnancies complicated with previable threatened labour with intact membranes.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Phase 3
Poissy, 78300, France
Observational data suggest that subclinical infectious conditions can lead to spontaneous preterm labor. 10% of births are premature, but the morbidity/mortality of premature babies is concentrated mainly among newborns born before 30 weeks of gestation or weighing less than 1500 g. The relationship to infection/inflammation and premature birth is not constant throughout pregnancy, but this infectious risk increases the earlier the gestational age of spontaneous labor is (before 30 weeks). The pathogens that have the strongest associations with premature birth are Gardnerella vaginalis, Ureaplasma urealyticum and Mycoplasma hominis, but also Streptococcus B, Escherichia coli, Klebsiella spp, or Haemophilus influenzae.
Antibiotic treatment to treat an intra-amniotic infection is considered ineffective. Indeed, the last randomized trial (Oracle 2, 2001), which studied several antibiotic regimens for threatened premature delivery with intact membranes, did not find a significant reduction in neonatal morbidity/mortality after administration of co-beta-lactam, erythromycin or the combination of both. In addition, this large trial dominates the results of the latest Cochrane meta-analysis which evaluated preventive antibiotic therapy to stop premature labor with intact membranes.
Recently, it has been showed that a new combination of antibiotics (ceftriaxone, clarithromycin and metronidazole) reduced the risk of infection and intra-amniotic inflammation in preterm labor with intact membranes. This retrospective study deserves to be confirmed by a randomized study
The investigator's goal is to study whether a new combination of antibiotics in a very limited population of pregnancies complicated by the threat of late miscarriage would make it possible to prolong pregnancies in order to improve neonatal outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ceftriaxone : 1g/day parenteral clarithromycin 500 mg*2/day orally metronidazole 500mg*3/ day orally
Other names: Ceftriaxone; clarithromycin, metronidazole
Emergency cerclage
Vaginal progesterone
Time frame: Up to 24 weeks
Time frame: 6 months
Time frame: 6 months
Chorioamniotitis, postpartum endometritis , sepsis proven par positive hemocultures
Time frame: 6 months
Acquisition of multi-resistant germs during childbirth
Contact information is provided by the study sponsor or research team.
Charly LARRIEU
CONTACT
Thibaud QUIBEL, MD, PhD
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
A Combination of Antibiotics to Decrease Neonatal Mortality and Morbidity for Pregnancies Complicated With Previable Labour and Intact Membranes: a Multicenter, Open-label, Randomized and Controlled Trial
Acronym: ECHEC-MAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738224
Communication Disorders, Female Urogenital Diseases and Pregnancy Complications
Melbourne, Victoria, Australia
View Trial DetailsNCT07738874
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Durham, North Carolina, United States
View Trial DetailsNCT07736768
Avitaminosis, Behavior
Jackson, Mississippi, United States
View Trial DetailsNCT07716813
Agnosia, Breast Milk
Mersin, Turkey (Türkiye)
View Trial Details